UY32665A - Proteinas de union al antigeno - Google Patents
Proteinas de union al antigenoInfo
- Publication number
- UY32665A UY32665A UY0001032665A UY32665A UY32665A UY 32665 A UY32665 A UY 32665A UY 0001032665 A UY0001032665 A UY 0001032665A UY 32665 A UY32665 A UY 32665A UY 32665 A UY32665 A UY 32665A
- Authority
- UY
- Uruguay
- Prior art keywords
- proteins
- tnfa
- alpha
- union
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a combinaciones de antagonistas del TNFa(alfa) con antagonistas de VEGF para usar en el tratamiento de enfermedades del ojo y proporciona proteínas de unión a antígeno que se unen al TNFa(alfa) o a un receptor de TNFa(alfa) y/o al VEGF o a un receptor de VEGF.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18188709P | 2009-05-28 | 2009-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32665A true UY32665A (es) | 2010-12-31 |
Family
ID=42315551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032665A UY32665A (es) | 2009-05-28 | 2010-05-26 | Proteinas de union al antigeno |
Country Status (17)
Country | Link |
---|---|
US (1) | US20120076787A1 (es) |
EP (1) | EP2435075A2 (es) |
JP (1) | JP2012528112A (es) |
KR (1) | KR20140014405A (es) |
CN (1) | CN102458471A (es) |
AR (1) | AR076796A1 (es) |
AU (1) | AU2010251966A1 (es) |
BR (1) | BRPI1013807A2 (es) |
CA (1) | CA2763469A1 (es) |
EA (1) | EA201190273A1 (es) |
IL (1) | IL216260A0 (es) |
MX (1) | MX2011012691A (es) |
SG (1) | SG176202A1 (es) |
TW (1) | TW201106963A (es) |
UY (1) | UY32665A (es) |
WO (1) | WO2010136492A2 (es) |
ZA (1) | ZA201108586B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
KR101654141B1 (ko) * | 2009-12-22 | 2016-09-05 | 삼성전자주식회사 | 혈관 내피 세포 성장인자에 특이적으로 결합하는 폴리펩티드, 그를 포함하는 융합 단백질 및 그의 제조 방법 |
AU2011237442A1 (en) | 2010-04-07 | 2012-10-18 | Momenta Pharmaceuticals, Inc. | High mannose glycans |
WO2012125553A2 (en) | 2011-03-12 | 2012-09-20 | Momenta Pharmaceuticals, Inc. | N-acetylhexosamine-containing n-glycans in glycoprotein products |
WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
BR112013031762A2 (pt) * | 2011-06-16 | 2016-09-13 | Novartis Ag | proteínas solúveis para utilização como terapêuticos |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
EA028886B1 (ru) * | 2011-07-27 | 2018-01-31 | Глаксо Груп Лимитед | ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ |
EP2861068A4 (en) * | 2012-06-01 | 2016-04-13 | Momenta Pharmaceuticals Inc | METHODS ASSOCIATED WITH BEVACIZUMAB |
WO2013181575A2 (en) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
AU2013100071C4 (en) * | 2012-07-03 | 2013-05-02 | Novartis Ag | Device |
JOP20200175A1 (ar) * | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
DE202012011016U1 (de) * | 2012-07-03 | 2012-11-28 | Novartis Ag | Aflibercept-Spritze |
US20150297675A1 (en) * | 2012-08-28 | 2015-10-22 | Aaron Osborne | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
EP3967306A1 (en) | 2012-10-01 | 2022-03-16 | Mayo Foundation for Medical Education and Research | Cancer treatments |
UY35195A (es) * | 2012-12-18 | 2014-07-31 | Novartis Ag | Composiciones y metodos para proteinas de accion prolongada |
TWI498425B (zh) * | 2013-01-08 | 2015-09-01 | Nat Univ Tsing Hua | 層析濾紙型酵素連結免疫吸附分析法 |
EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
WO2014149067A1 (en) | 2013-03-15 | 2014-09-25 | Momenta Pharmaceuticals, Inc. | Methods related to ctla4-fc fusion proteins |
US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US10927154B2 (en) | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
KR20170020371A (ko) | 2014-06-16 | 2017-02-22 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
EP3292148B1 (en) | 2015-05-04 | 2024-01-24 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
AU2016304764C1 (en) | 2015-08-07 | 2023-06-01 | Imaginab, Inc. | Antigen binding constructs to target molecules |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
ES2878008T3 (es) * | 2015-09-17 | 2021-11-18 | Scripps Research Inst | Inmunoconjugados de dominio variable dual y usos de los mismos |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
CN109400709B (zh) * | 2015-11-13 | 2021-03-23 | 广东医科大学 | 双功能抗体及其用途 |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
US20190338013A1 (en) * | 2016-02-26 | 2019-11-07 | Imunexus Pty Ltd | Multi-Specific Molecules |
EP3432926A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT |
US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
RU2019105550A (ru) * | 2016-08-05 | 2020-09-07 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования |
WO2018045239A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Carrier-pd-l1 binding agent compositions for treating cancers |
CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
KR20230010817A (ko) | 2016-09-06 | 2023-01-19 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
SG11201908547VA (en) * | 2017-03-22 | 2019-10-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
KR20190138636A (ko) * | 2017-03-22 | 2019-12-13 | 제넨테크, 인크. | 안구 장애의 치료를 위한 최적화된 항체 조성물 |
US20210113660A1 (en) * | 2018-05-07 | 2021-04-22 | Olives Biotherapeutics Inc. | Pharmaceutical composition comprising ccn5 as active ingredient, for preventing or treating retinal diseases |
EP3938391A1 (en) * | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
WO2020183269A1 (en) * | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
EP3938392A1 (en) * | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CN112898412A (zh) * | 2019-12-03 | 2021-06-04 | 复旦大学 | 一种高稳定性类Fab抗体及其制备方法和应用 |
WO2021248048A2 (en) * | 2020-06-05 | 2021-12-09 | Development Center For Biotechnology | Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof |
CA3240607A1 (en) * | 2021-12-13 | 2023-06-22 | Jaewook YANG | Composition for treating macular degeneration comprising novel peptide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
EP2641919A3 (en) * | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
-
2010
- 2010-05-26 AR ARP100101813A patent/AR076796A1/es not_active Application Discontinuation
- 2010-05-26 CN CN2010800324392A patent/CN102458471A/zh active Pending
- 2010-05-26 JP JP2012512358A patent/JP2012528112A/ja active Pending
- 2010-05-26 MX MX2011012691A patent/MX2011012691A/es not_active Application Discontinuation
- 2010-05-26 EA EA201190273A patent/EA201190273A1/ru unknown
- 2010-05-26 KR KR1020117031303A patent/KR20140014405A/ko not_active Application Discontinuation
- 2010-05-26 AU AU2010251966A patent/AU2010251966A1/en not_active Abandoned
- 2010-05-26 EP EP10721160A patent/EP2435075A2/en not_active Withdrawn
- 2010-05-26 BR BRPI1013807A patent/BRPI1013807A2/pt not_active IP Right Cessation
- 2010-05-26 SG SG2011086402A patent/SG176202A1/en unknown
- 2010-05-26 WO PCT/EP2010/057246 patent/WO2010136492A2/en active Application Filing
- 2010-05-26 UY UY0001032665A patent/UY32665A/es unknown
- 2010-05-26 TW TW099116868A patent/TW201106963A/zh unknown
- 2010-05-26 US US13/322,213 patent/US20120076787A1/en not_active Abandoned
- 2010-05-26 CA CA2763469A patent/CA2763469A1/en not_active Abandoned
-
2011
- 2011-10-22 ZA ZA2011/08586A patent/ZA201108586B/en unknown
- 2011-11-10 IL IL216260A patent/IL216260A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201106963A (en) | 2011-03-01 |
IL216260A0 (en) | 2012-01-31 |
ZA201108586B (en) | 2013-05-29 |
EA201190273A1 (ru) | 2012-12-28 |
AU2010251966A1 (en) | 2011-12-22 |
JP2012528112A (ja) | 2012-11-12 |
WO2010136492A2 (en) | 2010-12-02 |
CA2763469A1 (en) | 2010-12-02 |
KR20140014405A (ko) | 2014-02-06 |
SG176202A1 (en) | 2011-12-29 |
EP2435075A2 (en) | 2012-04-04 |
US20120076787A1 (en) | 2012-03-29 |
CN102458471A (zh) | 2012-05-16 |
BRPI1013807A2 (pt) | 2019-09-24 |
WO2010136492A3 (en) | 2011-02-24 |
AR076796A1 (es) | 2011-07-06 |
MX2011012691A (es) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32665A (es) | Proteinas de union al antigeno | |
SV2011003880A (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
PE20170256A1 (es) | Proteinas de union y sus metodos de uso | |
BR112012013876A2 (pt) | proteínas de ligação do antígeno humano que ligam o seu b-klotho, receptores de fgf e seus complexos | |
CR20120105A (es) | Proteínas terapéuticas de unión a dll4 | |
CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
EA201170242A1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
PH12015502007A1 (en) | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFa | |
EA201390254A1 (ru) | Модифицированные полипептиды релаксина и их применение | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
BR112016023948A2 (pt) | proteínas fc multiméricas | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
GT201300319A (es) | Coagonistas del receptor de glucagón / glp-1 | |
GT201200132A (es) | Antagonistas il-17a | |
MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
MX2016008099A (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40. | |
CO6670524A2 (es) | Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión | |
UY33983A (es) | Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento. | |
EA201270769A1 (ru) | Антитела к cgrp | |
CL2012003187A1 (es) | Proteinas de union a il-1 beta humana y ala il-1 alfa humana; conjugado de dicha proteina de unión; composicion para la liberacion de una proteina de unión; composicion farmaceutica. | |
CR20120210A (es) | Proteínas de enlace al antigeno il-23 humanas | |
CO6650372A2 (es) | Proteínas de unión de dominio variable dual que se unen a tnfy tweak, y métopdos para hacer y usar dichas proteínas | |
EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
CL2012003094A1 (es) | Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer. | |
EA201290541A1 (ru) | Модифицированные бычьи соматотропиновые полипептиды и их применение |